Polypeptide Group Ag · SIX:PPGN
Polypeptide — Healthcare Investor Meeting 2026
9 slides from Polypeptide's conference presentation, Mar 31, 2026
Slide 1: PolyPeptide Group AG Healthcare Investor Meeting 2026
PolyPeptide Group AG Healthcare Investor Meeting 2026 31.03.2026 Genolier, Switzerland
Slide 2: Disclaimer
2 Disclaimer This presentation (the "Presentation") has been prepared by operates. While the Group believes that such research and Alternative Financial Performance Measures (APM) PolyPeptide Group AG (“PolyPeptide” or the “Group”). The estimates are reasonable and reliable, they, and their underlyi
Slide 3: PolyPeptide is a leader in outsourced peptide APIs
PolyPeptide is a leader in outsourced peptide APIs 6 Multi-site network with cGMP-certified Over 70 years’ experience development and manufacturing facilities of manufacturing APIs global presence — Europe, USA, India a leading CDMO in peptides Custom projects pipeline with 195 active projects suppo
Slide 4: 2025 with strong growth and marked improvement in profitability
2025 with strong growth and marked improvement in profitability Growth in revenue and profitability • +16.0% revenue increase versus 2024 at constant currency rates, mainly driven by metabolic therapeutics • EBITDA margin improving +4.5 percentage points to 12.0% in 2025; EBITDA of EUR 46.8 million
Slide 5: Peptides - one of the most attractive markets for CDMOs
Peptides - one of the most attractive markets for CDMOs Global therapeutic peptide market potential1 Peptide drugs in clinical development2 (USD bn) (Phase 1-3, Pre-registration) Total 572, split by therapeutic area in % ~175 Metabolic CAGR ~15% Oncology Neurology 22% CAGR Cardiovascular 33% ~15% In
Slide 6: PolyPeptide's metabolic revenues have more than tripled since 2021
PolyPeptide’s metabolic revenues have more than tripled since 2021 Revenue by therapeutic area (EUR m) PolyPeptide’s broad exposure to metabolics2: CAGR1 389 15.5% • Metabolic increased from 22% of total revenue in 2021 to 57% of total revenue in 2025 282 169 1.9% • 37 metabolic development projects
Slide 7: Strong organic revenue growth, continued EBITDA improvement: well-positioned to achieve 2028 outlook
Strong organic revenue growth, continued EBITDA improvement: PolyPeptide is well-positioned to achieve 2028 outlook 2023A 2024A 2025A 2026 Guidance 2028 Outlook Revenue 337 389 20% to 25% EUR m 320 Double 2023 revenue (+5.1% growth) (+15.6% growth) growth vs. 20251 EBITDA -1.9% 7.5% 12.0% Mid- to hi
Slide 8: Thank you
Thank you PolyPeptide Group AG polypeptide.com
Slide 9: *|% PolyPeptide
*|% PolyPeptide